“Morphic continues to execute our strategy with the EMERALD-2 phase 2b study in ulcerative colitis (UC) recruiting on target, and we are excited to begin enrollment in the GARNET phase 2 study in patients with moderate to severe Crohn’s disease,” commented Praveen Tipirneni, CEO of Morphic Therapeutic. “We look forward to continued progress both with MORF-057 and our earlier-stage pipeline, including our program in pulmonary hypertensive diseases. Morphic is well positioned as the EMERALD-2 data approaches and GARNET commences, with a strong cash position and a strengthened leadership team following the addition of Dr. Simon Cooper as Chief Medical Officer.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MORF:
- Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
- Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
- Morphic appoints Cooper as Chief Medical Officer
- Morphic Holding Unveils Updated Corporate Presentation
- Morphic price target lowered to $66 from $68 at Canaccord